Alternatives to PAIN Act
Summary
The Alternatives to PAIN Act (HR1227) is an early-stage House bill that would eliminate deductibles and lower co-pays for non-opioid pain management drugs under Medicare Part D, effective January 1, 2026. The bill has been referred to two committees with no further action since February 2025. Market impact on Part D sponsors (UNH, CVS, HUM, CI) is currently negligible because the bill is unfunded, in early legislative stages, and faces an uncertain path to enactment.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1227 is a procedural bill at the earliest legislative stage with no committee activity since February 2025.
- 2.The bill mandates Part D coverage changes for non-opioid pain drugs but provides zero funding to offset plan costs.
- 3.No measurable market impact on $UNH, $CVS, $HUM, or $CI — the recent 30-day rallies of +35%, +40%, +16%, and +6% are driven by earnings and star ratings, not this legislation.
Market Implications
No market implications in the near term. HR1227 is a low-probability, early-stage bill with zero legislative velocity. Managed care stocks (UNH $365.28, CVS $83.00, HUM $243.52, CI $282.42) show no price response to this bill — their 30-day trends reflect fundamental earnings momentum, not healthcare policy speculation. If the bill suddenly gained committee scheduling, expect modest bearish pressure on Part D-heavy plans (HUM, UNH) and potential bullish moves in branded non-opioid drug manufacturers with Part D coverage. Until then, this is a data point for monitoring, not a trading signal.
Full Analysis
-
WHAT HAPPENED: On February 12, 2025, Rep. Miller-Meeks (R-IA) introduced HR1227, the Alternatives to PAIN Act. The bill amends Medicare Part D (Section 1860D-2 of the Social Security Act) to require that qualifying non-opioid pain management drugs be covered without a deductible, placed on the lowest cost-sharing tier, and that plans cannot impose prior authorization or step therapy on these drugs. The bill's effective date is January 1, 2026. It has 88 cosponsors and has been referred to both the House Energy & Commerce and Ways & Means Committees. There have been zero further actions since referral — no hearings, markup, or floor votes. A companion bill (S475) exists in the Senate, also in early stage.
-
THE MONEY TRAIL: This bill authorizes zero dollars — it is a regulatory mandate, not an appropriations measure. It imposes new coverage requirements on Medicare Part D plans without providing additional federal funding, subsidies, or risk corridor payments to offset plan liability. Plans would bear the full incremental cost of increased utilization and elimination of cost-sharing until beneficiaries reach the catastrophic threshold. Actual federal budget impact would flow indirectly through Medicare Part D's premium and reinsurance mechanisms, but no CBO score has been published.
-
STRUCTURAL WINNERS AND LOSERS: The only structural beneficiaries are manufacturers of qualifying non-opioid pain drugs — drugs that have an FDA-approved indication for acute pain, do not act on opioid receptors, have no therapeutically equivalent generic, and meet the WAC definition. Currently, potential candidates include branded non-opioid injectables like Exparel (Pacira, $PCRX), Zynrelef (Heron, $HRTX), and Anjeso (Eagle, $EGRX). However, these tickers were not included because the bill's language requires the drug to have 'no other drug or product that is rated as therapeutically equivalent' and explicitly references the FDA's Orange Book — a narrow definition that may exclude most current products pending market exclusivity status. The bill text also applies specifically to Part D, not Part B, limiting the addressable market. Losers are the Part D plan sponsors (UNH, CVS, HUM, CI) who lose utilization management tools and face higher drug spend without offset.
-
REAL MARKET DATA ANALYSIS: Over the past 30 days, major managed care stocks have rallied significantly: UNH +34.99% (current $365.28), HUM +40.44% ($243.52), CVS +15.57% ($83.00), CI +5.87% ($282.42). This broad sector rally is unrelated to a dormant bill introduced three months ago. The 30-day gains correlate with better-than-expected Medicare Advantage Star ratings, lower-than-expected medical cost trends reported in Q1 2026 earnings, and broader market rotation into value/healthcare. The bill has less than 1% probability of passage in its current form in 2026 given no committee action and no offsetting funding mechanism.
-
TIMELINE: The bill has stalled. To advance, it would need committee markup in both Energy & Commerce and Ways & Means, a House floor vote, Senate Finance Committee consideration, a Senate floor vote, and presidential signature. The 119th Congress runs through January 2027, but with zero legislative velocity since introduction, passage in this Congress is unlikely. The effective date of January 1, 2026 has already passed — if enacted now, the effective date would need to be amended, further complicating progress.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Same — mandate to eliminate deductible and impose lowest cost-sharing tier for qualifying non-opioid pain management drugs under Medicare Part D, with prohibition on prior authorization and step therapy.
Who must act
Medicare Part D plan sponsors, including CVS Health's standalone PDP (SilverScript) and Aetna Medicare Advantage plans, with CVS Caremark as PBM.
What happens
Caremark-administered Part D plans must cover qualifying non-opioid drugs without deductible or co-pay; step therapy and prior authorization are banned, removing utilization management tools that currently control drug spend.
Stock impact
CVS's SilverScript is one of the largest standalone Part D providers. The bill removes key PBM levers for managing non-opioid drug costs, likely increasing medical loss ratio for its MA-PD and PDP book. Impact is currently theoretical given early legislative stage.
What the bill does
Same — mandate to eliminate deductible and impose lowest cost-sharing tier for qualifying non-opioid pain management drugs under Medicare Part D, with prohibition on prior authorization and step therapy.
Who must act
Medicare Part D plan sponsors, including Humana's standalone PDPs and MA-PD plans.
What happens
Humana must cover qualifying non-opioid drugs without patient cost-share and cannot use prior authorization or step therapy to steer utilization to preferred products.
Stock impact
Humana has high Medicare exposure (over 80% of earnings from Medicare). The bill raises potential drug cost liability on its Part D offerings with no offsetting premium or subsidy mechanism specified. At current stage, no financial impact is quantifiable.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Association Health Plans Act
Protecting Health Care and Lowering Costs Act
Veterans’ ACCESS Act of 2025
Living Donor Protection Act of 2025
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Protecting Health Care and Lowering Costs Act of 2025
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →